Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07555938 · ClinicalTrials.gov registry record · Phase 3
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
A Phase 3 study, sponsored by Hoffmann-La Roche.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 380
- Enrollment target
NCT07555938 is a Phase 3 study that is actively recruiting participants, run by Hoffmann-La Roche. The registered enrollment target is 380 participants.
The verdict
NCT07555938, a Phase 3 study, is actively recruiting participants, sponsored by Hoffmann-La Roche.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 380 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.
Interventions
- DRUG Dexamethasone
- DRUG Daratumumab
- DRUG Pomalidomide
- DRUG Elotuzumab
- DRUG Cevostamab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2026-06-30 |
| Est. Completion | 2033-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07555938
The ClinicalTrials.gov registry entry for NCT07555938 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoffmann-La Roche, which has 909 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Dexamethasone is the first listed.
NCT07555938 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07555938 about?
NCT07555938 is a clinical study titled "Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma". The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD...
What is the current status of trial NCT07555938?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 380 participants. The study started on 2026-06-30. Estimated completion is 2033-01-31.
What interventions are being tested in trial NCT07555938?
The interventions under investigation include: Dexamethasone (DRUG), Daratumumab (DRUG), Pomalidomide (DRUG), Elotuzumab (DRUG), Cevostamab (DRUG).
Who is sponsoring clinical trial NCT07555938?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.